Literature DB >> 17535947

Quality of care in a Medicaid population with bipolar I disorder.

Alisa B Busch1, Haiden A Huskamp, Mary Beth Landrum.   

Abstract

OBJECTIVE: This study examined whether presenting diagnosis and treatment in intensive settings (hospitalization, partial hospitalization, or residential programs) are correlated with the subsequent treatment of bipolar I disorder.
METHODS: Claims data were studied retrospectively (fiscal years 1994-2000) for 2,644 patients with bipolar I disorder who had been enrolled in Medicaid at least six months before their first observed bipolar diagnosis. Logistic regression models estimated the association between the presenting diagnosis and initial treatment setting and the subsequent treatment up to one year after the first observed bipolar diagnosis. Measures included receipt of guideline-recommended care (antimanic agent plus psychotherapy) or care discouraged by guidelines (an antidepressant without an antimanic agent).
RESULTS: Only one-third of enrollees received both guideline-recommended treatments after the first observed bipolar diagnosis. Patients were less likely to receive both recommended treatments if the first observed mental health service occurred in an intensive setting. Enrollees presenting with a bipolar diagnosis were less likely to receive psychotherapy, whereas rates of antimanic medication use were similar to those with other presenting diagnoses. Presenting with depression or anxiety or other, nonbipolar diagnoses was associated with a higher likelihood of receiving pharmacotherapy discouraged by guidelines.
CONCLUSIONS: This study raises general concerns for the treatment quality of bipolar I disorder in this medically complicated, largely disabled Medicaid population. Also, how bipolar I patients enter treatment can be associated with subsequent differences in treatment quality--information that can be useful to clinicians and policy makers when planning quality improvements to treatment programs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17535947     DOI: 10.1176/ps.2007.58.6.848

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  9 in total

1.  Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder.

Authors:  Christine Y Lu; Alyce S Adams; Dennis Ross-Degnan; Fang Zhang; Yuting Zhang; Carl Salzman; Stephen B Soumerai
Journal:  Psychiatr Serv       Date:  2011-02       Impact factor: 3.084

2.  Implementing composite quality metrics for bipolar disorder: towards a more comprehensive approach to quality measurement.

Authors:  Amy M Kilbourne; Carrie Farmer Teh; Deborah Welsh; Harold Alan Pincus; Elaine Lasky; Brian Perron; Mark S Bauer
Journal:  Gen Hosp Psychiatry       Date:  2010-10-30       Impact factor: 3.238

3.  The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.

Authors:  Catherine A Fullerton; Alisa B Busch; Richard G Frank
Journal:  Med Care       Date:  2010-04       Impact factor: 2.983

4.  Customization in prescribing for bipolar disorder.

Authors:  Dominic Hodgkin; Joanna Volpe-Vartanian; Elizabeth L Merrick; Constance M Horgan; Andrew A Nierenberg; Richard G Frank; Sue Lee
Journal:  Health Econ       Date:  2011-04-19       Impact factor: 3.046

5.  Bipolar-I patient characteristics associated with differences in antimanic medication prescribing.

Authors:  Alisa B Busch; Richard G Frank; Gary Sachs; Sharon-Lise T Normand
Journal:  Psychopharmacol Bull       Date:  2009

6.  Treatment use and costs among privately insured youths with diagnoses of bipolar disorder.

Authors:  Stacie B Dusetzina; Joel F Farley; Morris Weinberger; Bradley N Gaynes; Betsy Sleath; Richard A Hansen
Journal:  Psychiatr Serv       Date:  2012-10       Impact factor: 3.084

7.  Performance indicators for public mental healthcare: a systematic international inventory.

Authors:  Steve Lauriks; Marcel Ca Buster; Matty As de Wit; Onyebuchi A Arah; Niek S Klazinga
Journal:  BMC Public Health       Date:  2012-03-20       Impact factor: 3.295

8.  Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service.

Authors:  Sabrina Paterniti; Jean-Claude Bisserbe
Journal:  BMC Psychiatry       Date:  2013-08-13       Impact factor: 3.630

9.  A nationwide study on concordance with multimodal treatment guidelines in bipolar disorder.

Authors:  Joannes W Renes; Eline J Regeer; Adriaan W Hoogendoorn; Willem A Nolen; Ralph W Kupka
Journal:  Int J Bipolar Disord       Date:  2018-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.